Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug (TNT119) in Subjects With Immune Thrombocytopenia (ITP)

NCT07043946 is registered in ClinicalTrials.gov with Climb Bio, Inc. as lead sponsor.

NCT NCT07043946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07043946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug (TNT119) in Subjects With Immune Thrombocytopenia (ITP)
Lead sponsor
Climb Bio, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 30, 2025
Completion date
August 31, 2028
Enrollment
24 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

anti-cd19, biologics, immune thrombocytopenia (itp), itp, monoclonal